Newer therapies - DiabetesontheNet

Novel antidiabetes drugs improve composite renal outcomes

Absolute treatment benefits of GLP-1 RAs and SGLT2 inhibitors on renal outcomes revealed.

18 Mar 2024

Novel antidiabetes drugs improve composite renal outcomes

Absolute treatment benefits of GLP-1 RAs and SGLT2 inhibitors on renal outcomes revealed.

18 Mar 2024

Editorial: Lipid management, tirzepatide and hybrid closed-loop: What does new NICE guidance recommend?

With a raft of newly published NICE guidance, Jane Diggle discusses the implications for practice in primary care.

6 Mar 2024

Diabetes Distilled: Metformin does not increase risk of GI side effects during GLP-1 RA initiation and titration

No benefit to pausing metformin therapy during GLP-1 RA initiation.

6 Mar 2024

Latest news: Tirzepatide prefilled pen; remission and cardiorenal benefits; and low-energy diets in primary care

Stay abreast of the latest news that could impact diabetes nursing.

29 Feb 2024

Rising to the challenges of a new year

Su Down looks forward to new opportunities that this year will present.

22 Feb 2024

Tirzepatide to be available in prefilled injection pen

Marketing authorisation given for GIP/GLP-1 agonist as four-dose KwikPen.

8 Feb 2024

Tirzepatide to be available in prefilled injection pen

Marketing authorisation given for GIP/GLP-1 agonist as four-dose KwikPen.

8 Feb 2024

Incretins: How we got here, where we’re at and what is coming next

The incretins, diabetes and cardiorenal disease: an evolving story.

18 Jan 2024

Diabetes Distilled: Reaching a XENITH in cardiorenal protection

Phase 2b study demonstrates significant reductions in uACR with developmental drug zibotentan plus dapagliflozin, compared with dapagliflozin alone.

10 Jan 2024

Diabetes Distilled: DELIVERing reassurance that early eGFR reductions with SGLT2 inhibitors should not prompt drug discontinuation

Initial eGFR reductions of >10% when starting SGLT2 inhibitors are not associated with adverse cardiovascular or renal outcomes.

10 Jan 2024

Diabetes Distilled: “Twincretin” tirzepatide significantly SURPASSes comparator effects on glucose, weight and quality of life

Will this highly effective new agent change current treatment guidelines, especially with regard to glycaemic and weight loss targets?

10 Jan 2024

Another year over, but what can we look forward to next year?

Su Down anticipates exciting opportunities for diabetes care in 2024.

18 Dec 2023

Journal club: New kids on the block – friend or foe?

New therapies show great potential, but at what cost?

27 Nov 2023

New kids on the block: Friend or Foe?

Amid accumulating evidence of benefits with new diabetes drugs, Vinod Patel asks whether the costs can be justified.

9 Nov 2023

Tirzepatide reduces the predicted risk of developing type 2 diabetes

Predicted relative risk of type 2 diabetes reduced by about half at 24 weeks and by about two-thirds at 72 weeks.

9 Nov 2023

Effects of canagliflozin are consistent across BMI classes

Cardiovascular and renal outcomes are similar in people with type 2 diabetes irrespective of BMI category.

9 Nov 2023

Benefits and adverse events of newer diabetes therapies according to frailty status

SGLT2 inhibitors and GLP-1 RAs superior to DPP-4 inhibitors even in people with high frailty scores.

9 Nov 2023